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1. BACKGROUND 
Congenital heart defects have a reported incidence of 4 to 8 per 1000 live births and 
encompass a broad spectrum of disorders1. Exercise capacity is reduced across the 
spectrum of patients with congenital heart defects (CHD), both in natural history and 
after surgical and interventional treatment 2,3. Due to advances in cardiac surgery 
and cardiology care, most children born with CHD are now surviving into adulthood 
and there are currently more adults with congenital heart disease than children. 
Despite these advances, many young adults with CHD are at risk for premature 
death with heart failure being one of the leading causes of death. It is well 
recognised that exercise capacity is impaired across the broad spectrum of 
congenital heart lesions. This is clearly expected in complex anatomies that go 
down the univentricular palliation pathways but also milder lesions have been 
demonstrated to lead to exercise limitation 2.  
Two percent of children with CHD have a single functioning ventricle. Single 
ventricle hearts comprise a heterogeneous group of defects which are not suited for 
a two ventricle repair. The Fontan procedure, originally described by Fontan and 
Baudet 4 in 1971, has been a major contribution in improving the quality of life and 
survival of children and adolescents with cyanotic congenital heart disease who 
were limited in their physical activities and at high risk of premature death3. The 
primary indication of this procedure was to palliate tricuspid atresia. The procedure 
was designed to deviate the venous return from the superior and inferior vena cavae 
through the pulmonary arteries, with the right atrium being used to propel the 
venous return through the lungs. Thus, partial restoration of the pulmonary blood 
flow was achieved, alleviating the mixed arterial and venous blood characteristic of 
this malformation. This was introduced to obtain normal oxygenation and to avoid 
volume overloading. Several modifications of the Fontan procedure have been 
developed to address the single functional ventricle in general. The ‘Fontan 
circulation’ procedure connects the systemic venous return to the pulmonary arteries 
without the interposition of an adequate ventricle and all shunts at the venous, atrial, 
ventricular and arterial level are interrupted 5. Patients with a Fontan circulation 
possess a unique physiological response to exercise. This procedure confers a 
significant survival benefit, relief of cyanosis and improvement of approximately 20% 
in exercise tolerance. In fact, patients have a 30% to 40% lower exercise tolerance 
than that of healthy, age-matched controls 6. Patients who have had a Fontan 
procedure constitute an heterogeneous group. Indeed, there are significant 
hemodynamic differences between the different Fontan procedures (for example, a 
classic Fontan procedure compared with an extracardiac Fontan procedure). A 
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single left ventricle Fontan patient cannot be compared with a single right ventricle 
Fontan patient. Several limitations of the cardiorespiratory functions may explain this 
reduced exercise tolerance. Although the population of patients with a Fontan 
procedure is heterogeneous, they share similar physiological and metabolic 
adaptations during exercise. 
Among the different screening tools employed during periodic follow-up, 
cardiopulmonary exercise testing (CPET) has emerged as one of the most valuable. 
It is non-invasive, enables risk stratification with regard to morbidity and mortality, 
and helps deciding on the need and timing of therapeutic interventions. Previous 
studies have suggested that exercise intolerance is a powerful prognostic marker in 
patients with CHD establishing an association between exercise intolerance and 
increased morbidity and mortality 2. More recently studies have shown the 
prognostic value of parameters of cardiopulmonary testing in patients with a 
systemic right ventricle or corrected Tetralogy of Fallot. 
Reduced exercise capacity (peak oxygen uptake (VO2)) can be related to abnormal 
cardiovascular haemodynamics during exercise (inappropriate increase in stroke 
volume or heart rate to exercise), abnormal perfusion of the exercising muscles, 
abnormal extraction of O2 from the exercise muscles, and abnormal O2 content 
(hypoxemia or anemia). 
However, these variables alone often do not fully explain the exercise limitations 
found in this young population. Data collected in patients with heart failure from 
acquired cardiomyopathy (ischemic or dilated) suggest exercise limitation is often 
due also to a generalized myopathy 7. The cause of this myopathy is not well 
understood and is thought to be multifactorial. The myopathy can involve the 
peripheral skeletal muscles and the respiratory muscles 8,9,10, particularly the 
diaphragm, and can have an impact on aerobic capacity and on respiratory 
response to exercise 11-14. 
In the last decade it has been recognized that adults with CHD suffer a heart failure 
syndrome which is identical to the one observed in patients with acquired heart 
disease 15, 16. There is evidence that patients with CHD have reduced skeletal and 
respiratory muscle strength, as assessed by maximal inspiratory and expiratory 
pressures at rest and 10 minutes after maximal exercise. This evidence exists for 
patients with repaired tetralogy of Fallot, Fontan operation and Musterd/Senning 
operation 17. Furthermore it is noteworthy that CHD patients suffer from a life-long 
detraining as exercise limitations are  often imposed since childhood  independently 
of the pathology as a remnant of clinical and social fears 18. 
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Decreased skeletal and respiratory muscle strength is associated with poor 
outcomes in patients with heart failure and is a target for specific treatment with 
aerobic exercise and respiratory muscle training to improve functional capacity and 
quality of life 19,20,21. In recent years an effort as been made to understand to which 
extent the exercise intolerance observed in CHD patients is due to skeletal and 
respiratory muscle weakness and if exercise and respiratory training may help 
improving quality of life and survival 22,23,24. 
2. AIMS 
The aim of this project was to better understand exercise limitations and 
safety/usefulness of exercise training in young patients (children and young adults) 
with heart diseases across a broad spectrum of diagnosis and in particular we 
focused on left to right shunts, systemic right ventricular physiology, univentricular 
physiology with Fontan palliation and dilated cardiomyopathy. 
Looking at future perspective we are currently exploring new ways of engaging 
teenagers with univentricular palliation in systemic and respiratory muscle training. 
Also, in collaboration with biomedical engineers we are modelling the univentricular 
circulation looking at outcomes on the basis of the anatomical shape and their 
haemodynamic repercussion on the cavopulmonary connection.  
Similarities exisit in the physiological changes observed during exercise and 
pregnancy and the final goal is to implement the model with these physiological 
variables to gain in depth understanding of this physiology and how we can achieve 
better clinical outcome in this growing population of young adults with complex 
lesions and limited exercise and child-bearing potential.  
2.1 EXERCISE CAPACITY IN LEFT TO RIGHT SHUNTS  
2.1.1INTRODUCTION 
A left-to-right shunt lesion exists when blood from the left atrium, left ventricle, or 
aorta transits to the right atrium or its tributaries, the right ventricle, or the pulmonary 
artery. In these conditions blood from the systemic arterial circulation mixes with 
systemic venous blood. The presence of a left-to-right shunt results in a volume 
overload of one or more cardiovascular chambers or structures. Multiple factors 
influence the extent of flow through the shunt and its physiologic effects. If the shunt 
is significant, blood flow and pressure in the pulmonary circulation become 
abnormally high. At the same type the amount of blood which reaches the systemic 
circulation (cardiac output) can be reduced, particularly during exercise. Over time, 
there is progressive damage to the pulmonary vasculature endothelium and gradual 
development of irreversible pulmonary vascular changes and pulmonary 
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hypertension. The resistance in the pulmonary circulation may ultimately exceed the 
systemic resistance with reversal of blood flow from the right side of the circulation 
to the left (Eisenmenger syndrome) evident as cyanosis either at rest or during 
exercise. Lesions resulting in left to right shunts include: (1) Atrial septal 
defect (ASD); (2) Ventricular septal defect (VSD); (3) Patent ductus arteriosus 
(PDA); (4) Large coronary artery fistulas. While wide consensus exists in the 
management of significant shunts, it is not always clear when and how it is time to 
intervene on smaller defects. We will review the evidence supporting a role of 
exercise testing in the assessment of children and adults with left-to-right shunt and 
the effect of abolishing left-to right shunt on exercise. 
2.1.2 ATRIAL SEPTAL DEFECTS 
Atrial septal defects are the most common form of congenital heart defect and occur 
in 1 child in 1,500 live births 25. Of the various types classified in base of the 
anatomic location, ostium secundum ASDs represent 6% to 10% of all cardiac 
anomalies. In the setting of a large inter-atrial communication, a chronic left-to-right 
shunt creates a volume overload on the right-sided cardiac structures and results in 
dilation of the right atrium and right ventricle. The chronic volume overload causes 
dilation of the entire pulmonary vascular bed. Pulmonary blood flow is increased, 
often up to three to four times normal. However, the pulmonary artery pressure is 
only slightly increased, and in most patients, pulmonary resistance remains in the 
normal range. 
Most infants and children with ASDs are asymptomatic. Rarely, ASDs are 
associated with poor growth, recurrent lower respiratory tract infection, and heart 
failure. Children with large left-to-right shunts are likely to complain of some fatigue 
and dyspnea. The natural course of ASDs is relatively benign except for those with 
persistent significant left-right shunt. Typically, patients with smaller ASDs remain 
active and asymptomatic through early childhood, and many patients have lived into 
their fourth, fifth, sixth, and even seventh decades with ASDs of moderate size 
before symptoms developed 26. Congestive heart failure rarely is found in the first 
decades of life, but it becomes more common with advancing age. The same can be 
said for the incidence of atrial arrhythmias with the associated risk of stroke and 
paradoxical embolism 25. In a few patients (5-10%) with a secundum ASD, severe 
and irreversible hypertensive pulmonary vascular disease may develop[3]. As 
cardiac catheterisation used to performed as a diagnostic step in many patients with 
an ASD, indication on closure was predominantly based on haemodynamic data, 
particularly the extent of the ratio between pulmonary blood flow and systemic blood 
flow (Qp/Qs). 
It is generally accepted that elective closure of ASD is the treatment of choice if 
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pulmonary-to-systemic blood flow ratio is >1.5. However, many children now do no 
undergo cardiac catheterisation as a diagnostic step and invasive criteria have been 
replaced by echocardiographic criteria. The main criteria for posing the indication to 
ASD closure is the presence of more than mild right heart dilatation or signs of 
increased right ventricular systolic pressure in the face of significant left-right shunt 
(which can also measured by echocardiography). Additional qualitative criteria are 
the presence of increased venous return from the pulmonary veins and dilatation of 
the main pulmonary artery. Elective surgical repair of ASDs has been a safe and 
simple operation in the hands of an experienced surgical team. It has been the first 
treatment of choice for children with large defects in the last 50 years and there is a 
large body of medical research covering long term results. Since most ASDs are 
well tolerated in infancy and may spontaneously close, elective repair frequently has 
been deferred until the child is at least 4 years of age. 
Trans-catheter techniques for closure of ostium secundum ASDs have been 
available for several years. In 1976, King et al reported the first trans-catheter 
closure of a secundum ASD in humans with a double-umbrella device 27,28 . The 
availability of non-surgical ASD closure has led to an increase in the number of the 
defects being closed[5] and has perhaps also lowered the bar for some defects to 
be considered for closure. Trans-catheter closure has the advantage of avoiding the 
need for sternotomy, cardiopulmonary bypass and intensive care stay and facilitates 
rapid patient recovery when the anatomy of the defect is suitable. However still 
nowadays younger patients or those with very large defects or small/absent defect 
margins require surgical closure. 
2.1.2.1 EXERCISE TOLERANCE IN CHILDREN TREATED FOR ASD 
Data are now available on long term follow-up of patients who underwent surgical 
ASD closure during childhood. Despite a clear improvement in the morbidity of these 
patients, there is still ongoing debate on whether children with ASD which undergo 
surgical closure can achieve the same life expectancy of healthy peers if treated 
timely. Cuypers et al recently published very long-term (30-41 years) outcome after 
surgical ASD closure in childhood and showed excellent survival and low morbidity. 
The general health and exercise capacity of the patients reported were comparable 
to the healthy Dutch population. They reported no pulmonary hypertension but 
persistent right ventricular dilation at magnetic resonance imaging despite a long 
follow-up from closure 30. In the recent study by de Koning et al, exercise testing did 
not reveal differences between patients who underwent surgical ASD closure in 
childhood and healthy reference population. In line with Cuypers et al they found 
right ventricular end-systolic volume remained increased in the long term after 
surgical closure without any impact on exercise capacity or onset of arrhythmias 31. 
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Only one study, by Massin et al, compared the outcome of children who underwent 
percutaneous ASD closure versus open surgery. The study showed no difference in 
peak VO2 but underlined a higher prevalence of chronotropic incompetence in the 
surgical group, even though this didn’t affect overall exercise capacity 32. In this 
setting chronotropic incompetence is thought to be secondary to the effect of the 
cannulation used to establish cardiopulmonary bypass. Previous studies showed a 
significant reduction in exercise tolerance in children with ASD 33 and failed to show 
a significant improvement after trans-catheter closure 33,34. Reasons for that might 
be the fact that study cohorts were small and that the follow up was limited to 3 
months, when research in young adults suggests that the process of normalisation 
of exercise capacity can take significantly longer than 3 months 35. No data is 
currently available on long term outcome of percutaneous closure in children.  
2.1.2.2 EXERCISE TOLERANCE IN ADULT PATIENTS TREATED FOR ASD 
At present ASDs accounts for up to 40% of congenital heart lesions detected in 
adults 40 years of age and older 36. Despite high pulmonary blood flow and right 
heart volume overload, patients with uncomplicated ASD often report only minor 
subjective complaints and do not recognise their reduced exercise tolerance. This is 
evident from the fact that several studies have shown reduced 
exercise capacity even in asymptomatic patients 37,38. Nakanishi and colleagues 
tested 18 adult ASD patients and found their peakVO2 was impaired (21.6±5.6 
mL/min/kg or 63.5±16.2% of predicted). They also observed that higher PAPm and 
higher Qp/Qs were related to lower exercise capacity 36. Oelberg et al tested 10 
adults with ASD and compared them to 10 matched healthy controls. Their patients 
were found to have reduced exercise performance, which could be associated with 
an abnormal increase in pulmonary artery pressure during exercise 39. In the past 
when only surgical procedures were available, only large ASDs would be advised for 
closure because they were considered likely to result over time in shunt reversal or 
heart failure. Adults with significant ASDs are advised to undergo surgical repair 
before the onset of pulmonary hypertension in order to increase longevity and limit 
the deterioration of functional capacity. Once pulmonary hypertension develops, 
irreversible right ventricular failure may result. However, it can be difficult to detect 
early stages of pulmonary vascular damage when pulmonary arterial pressures and 
pulmonary vascular resistance are still normal at rest but they can rise, instead of 
physiologically decrease, during exertion 40. Surgical series have shown discordant 
results on functional status following surgical ASD closure in adult patients, giving 
rise to concerns on the appropriate timing of intervention and patients selection. 
Fredriksen et al. compared exercise capacity in adults with congenital heart disease 
with healthy subjects and found that even patients with closed ASDs did not do as 
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well as controls in the long term 41. However, Helber et al showed a lack of 
improvement in exercise capacity early after surgical ASD closure in patients over 
the age of 40 years, but they suggested that the improvement in exercise capacity 
took place later as demonstrated by the complete normalisation observed 10 years 
after shunt closure 42. They observed that the improvement in exercise tolerance 
didn’t correlate with the size of the shunt but it correlated inversely with mean 
pulmonary pressure before closure. Kobayashi et al reported a larger cohort and 
stratified patients on the basis of the size of the shunt and the degree of pulmonary 
arterial hypertension. No peak VO2 improvement was shown in the group of patients 
with PAPm>30 mmHg, while those patients with significant shunts and lower 
pulmonary artery pressure did improve their exercise capacity following closure 43. 
The importance of finding abnormal and possibly exerciselimiting elevations in 
pulmonary artery pressure during exercise in ASD might also be important in the 
decision making regarding the timing of surgical closure. Van de Bruaene et al 
demonstrated older patients who underwent closure later on in life had a good 
overall cardiopulmonary capacity but didn’t normalise pulmonary haemodinamics, 
which was shown by the lack of physiological decrease of pulmonary vascular 
resistance on exertion 40. 
In recent years trans-catheter closure has become widely available and the results 
have proven to be at least as good as surgical closure in terms of mortality and 
functional capacity. Suchon et al compared the two techniques in an effort to 
demonstrate that, when dealing with favourable anatomy, percutaneous closure is a 
less costly option and guarantees the same results in the midterm. They 
demonstrated a low exercise capacity at baseline and a significant increase in 
oxygen uptake after both surgical and trans-catheter closure, as well as a significant 
decrease in minute ventilation/CO2 dioxide output. Their patients improved 
significantly their exercise capacity, irrespective of the actual method of closure, but 
patients with elevated right ventricular systolic pressures failed to normalise their 
peak VO2 44. Brochu et al assessed the effect of percutaneous ASD closure in 37 
asymptomatic or mildly symptomatic adults showing a significant and rapid 
improvement of exercise capacity and regression of right ventricular dilatation at 6 
months. The improvement in exercise capacity was irrespective of age, functional 
class, right ventricular enlargement, or baseline exercise capacity 38. Jategaonkar et 
al reported a significant decrease in right ventricular end-diastolic diameter and 
significant improvements of NYHA functional class and peak VO2 at 3 months from 
ASD device closure in all age groups, even in patients over 60 years old. However, 
little is known about long-term results in those patients 45. Our group evaluated the 
impact of trans-catheter ASD closure on right ventricular remodelling and exercise 
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capacity in asymptomatic adult patients with the aim of identifying the factors 
associated with a change in exercise capacity. We demonstrated that the 
improvement in peak VO2 is due to an improvement in peak O2 pulse. We also 
demonstrated that an increase in both left ventricular stroke volume and cardiac 
output due to a positive ventricular interaction is the mechanism leading to 
increased peak O2 pulse and peak VO2 37. We also demonstrated that the 
improvement is not limited to the 6 months period as a further cardiac remodelling 
and improvement in exercise capacity can be expected in the midterm 35,37. Another 
observation from our group is that device ASD closure can quicken the time taken to 
recover from maximal exercise, which might also have positive implications for 
patients. 
2.1.3 VENTRICULAR SEPTAL DEFECTS 
Ventricular septal defects account for approximately a third of the congenital cardiac 
defects diagnosed at birth. The magnitude of the left-to-right shunt is related directly 
to the size of the defect and pulmonary vascular resistance. Small VSDs are those 
less than one third the size of the aortic root and which impose a high resistance to 
flow with a resultant large pressure drop between the left and the right ventricle. In 
this case, the left-to-right shunt is small, right ventricular systolic pressure is normal, 
and there is no tendency for an increase in pulmonary vascular resistance. With 
large VSDs, a gradual decline of pulmonary vascular resistance usually occurs in 
the first few months of life, resulting in augmentation of the left-to-right shunt. The 
large blood volume handled by the left atrium results in left atrial and pulmonary 
venous hypertension. The increased return to the left side of the heart results in an 
enlarged left atrium and left ventricle as well as an increase in the left ventricular 
muscle mass. With the marked volume overload of the left ventricle, congestive 
heart failure is particularly likely to occur between the ages of 2 and 8 weeks. 
Compensatory mechanisms that allow the infant to adapt to this volume load include 
the Frank Starling effect, increased sympathetic cardiac stimulation, and myocardial 
hypertrophy. The rapidity of the development of myocardial hypertrophy is one of 
the major factors in the ability of an infant to compensate adequately for a VSD with 
a large left-to-right shunt. Excessive and high pressure pulmonary blood flow is 
associated with progressive pulmonary arterial vessel injury. Chronic injury 
associated with a large un-repaired VSD can result in a thickened adventitia, medial 
hypertrophy, and intimal injury resulting in pulmonary vascular obstructive disease 
25. Therefore, large VSDs with left-to-right shunt should undergo surgical repair 
within 1 year of age to prevent pulmonary vascular changes. Smaller defects can be 
followed up in time and a considerable portion is found to decrease in size and 
eventually spontaneously close 46,47. The long term outcome of this latter group 
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seems benign. When children with surgically closed VSDs or those with 
haemodynamically insignificant defects have undergone ECG exercise testing 
results have generally showed normal exercise capacity 47-50. A small number of 
studies concentrated on cardiopulmonary exercise testing in patients with VSDs. 
Binkhorst et al. showed no difference in peak VO2 in patients after surgical VSD 
closure, small VSDs left untreated and healthy controls. Perrault at al. compared a 
small cohort of repaired VSD patients to patients with repaired tetralogy of Fallot, 
patients with repaired ASD and healthy controls and found peak VO2 values were 
within the normal range in patients with closed VSDs. In both the previously 
mentioned studies, peak heart rate was found to be lower in surgical treated VSD 
patients, which is consistent with previous evidence of chronotropic limitations after 
cardiopulmonary bypass surgery in different types of congenital cardiac defects 51,52. 
Moller et al described 44 patients (17 surgically closed ASD, 11 surgically closed 
VSD, 16 restrictive VSD considered haemodinamically not significant and thus left 
open) who underwent cardiopulmonary exercise testing and exercise 
echocardiography. They found reduced exercise capacity in all patients groups 
when compared to a control group comprising 88 healthy subjects. The authors 
observed an abnormal right ventricular systolic pressure response to exercise even 
in those patients who did not have any signs of increased pulmonary artery pressure 
at rest before closure. This finding was confined to VSD patients alone, either closed 
(5/11 patients) or open (4/16 patients), whereas no ASD patients showed increased 
pulmonary pressure during exercise 53. 
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2.2 EXERCISE TRAINING IN SYSTEMIC RIGHT VENTRICLE 
2.2.1 INTRODUCTION 
The estimated prevalence of congenital heart disease (CHD) is 3 per1000 live 
births, and the number of these patients that survive until adulthood is steadily 
increasing 54 A substantial portion of these patients has a morphological right 
ventricle that sustains the systemic circulation, for instance patients with a 
transposition of the great arteries (TGA) after a Mustard or Senning operation, and 
patients with a congenitally corrected transposition of the great arteries (ccTGA). 
The large majority of adult patients with a systemic right ventricle is faced with 
deteriorating right ventricular function, and decreased exercise capacity 55. In 
patients with acquired congestive heart failure the European Society of Cardiology 
recommends patient's participation in a multidisciplinary care program, which 
includes exercise training, to reduce the risk of heart failure hospitalization 56. A 
study by O'Connor et al. showed an 11% reduction in all-cause mortality or all-cause 
hospitalization at 30 months of follow-up of a 3 month supervised training program, 
followed by a home-based training program 57. In our own study, ten weeks of 
exercise training improved exercise capacity in patients with a systemic right 
ventricle 58. In patients with acquired heart disease beneficial effects of exercise 
training are known to diminish as time from the training program progresses 59,60. 
However, it remains unclear whether the effects of exercise training in adult patients 
with a systemic right ventricle is only temporary or whether it constitutes a 
permanent effect, possibly due to lifestyle changes. Therefore, the primary objective 
of this study is to determine the long-term effects of a ten-week exercise training 
program in adult patients with a systemic right ventricle. 
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2.2.2 METHODS 
Study design 
The present study was a one-time cross-sectional re-evaluation at three years follow 
up of participants of the 2009 study “The effect of exercise in adult patients with a 
systemic right ventricle” (http://trialregister.nl id. NTR1909) 58. 
Participants 
All patients who participated in the 2009 study were eligible. These were adults with 
a systemic right ventricle due to congenitally or surgically corrected TGA. Patients 
who were mentally or physically incapable to participate in a home-based exercise 
program had been excluded, as were patients with experienced exercise-induced 
arrhythmia, symptomatic myocardial ischemia, a resting systolic blood pressure 
≥200 mm Hg and/or diastolic blood pressure ≥110 mm Hg, New York Heart 
Association (NYHA) class III or IV, pregnancy during the training period, and non-
cardiac co-morbidity that could affect exercise performance or that could aggravate 
by exercise. 
Study settings 
The study was conducted in the Netherlands (three sites) and Italy (one site). The 
study complies with the Declaration of Helsinki and was approved by the locally 
appointed Ethics Committee of all participating centers. Renewed informed consent 
was obtained from all participants prior to participation in the present re-evaluation. 
Interventions 
In 2009 consenting patients were randomized using unmarked opaque envelopes to 
an intervention group with three aerobics step training sessions per week for 10 
consecutive weeks, and a control group. The detailed exercise training protocol has 
been published previously 58. 
Sports participation 
Patients were asked to indicate 1) whether they currently participated in sports or 
physical exercise, 2) how many times they participated in sports or exercise and 3) 
with what intensity (light, medium, heavy). The answers were compared to the data 
of the original trial. Patients who participated in sports or those who exercised at 
least 1 weekly in an activity that scored 5 METS or more according to the 
Compendium of Physical Activities 60, were considered to be active in sports, while 
patients who scored below this threshold were not considered active in sports or 
exercise. 
Outcomes 
. Cardiopulmonary exercise testing 
Exercise testing was performed on an upright bicycle ergometer. After an initial 
calibration period of 2 min, workload was increased by 5–15 W/min in a stepwise 
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manner. The exercise protocol was identical to the tests performed in 2009. Breath-
by-breath analysis of minute ventilation, oxygen uptake (VO2), carbon dioxide 
elimination (VCO2), heart rate, blood pressure and electrocardiography was made. 
. Serum N-terminal pro-hormone of brain natriuretic peptide 
Samples were analyzed locally and in a standardized fashion. N-terminal 
prohormone brain natriuretic peptide assessment kits differed between participating 
centers, although the same kit was used for the same patient. 
. Quality of life 
Health-related quality of life was assessed by means of the Dutch and Italian 
translations of the Medical Outcomes Study Short Form 36 item(SF-36) health 
survey 58. The SF- 36 is a generic multi-item questionnaire comprising of 36 
questions on eight domains (physical functioning, role functioning physical, bodily 
pain, general health perception, vitality, social functioning, role functioning 
emotional, and mental health). Scores range from 0 to 100, with higher scores 
representing better quality of life. Patients' SF-36 scores were analyzed in 
comparison to published age- and gender-matched reference population norms, 
after which the eight domains were combined into two higher ordered clusters; the 
physical component summary and the mental component summary. In addition, the 
quality of life was assessed by means of the Dutch and Italian translations of the 
CHD-TNO/AZL Adult Quality of Life (CHD-TAAQOL) questionnaire 58. The CHD-
TAAQOL was developed as a disease specific tool for measuring health-related 
quality of life in adults with congenital heart defects. Scores were transformed to a 
0–100 scale, with higher scores representing better quality of life. 
Statistical analysis 
Data are expressed as numbers with percentage, as mean with standard deviation, 
or median with interquartile range (IQR) as appropriate. Analysis was intention-to-
treat. Chi-square and Students independent t-test were performed to evaluate 
whether the re-recruitment process might have imbalanced the study groups, the 
original grouping being the result of randomization. Changes from baseline in each 
group were evaluated using a two-tailed paired t-test or Wilcoxon matched pairs 
signed ranks test where appropriate. Significance and size of the treatment effect 
(intervention vs control) were determined by analysis of covariance. The analysis 
was adjusted for baseline values and participating center (to account for 
stratification). In addition, a sensitivity analysis including only those patients who 
completed the protocol in both 2009 and 2013 was performed. A 2-tailed p-value of 
<0.05 was used as a criterion for statistical significance. 
An exploratory multivariate analysis of covariance was performed to assess whether 
any determinants at baseline were associated with exercise capacity at follow-up. 
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Moreover, a composite endpoint of clinical events was defined similar to a previous 
publication 61. This included any arrhythmia, reoperation, thromboembolism, 
myocardial infarction, worsening heart failure, and death. Event-free survival was 
estimated using all available data (including chart review of non-participating 
patients). In patients with multiple events only the first event was used in survival 
analysis. Differences in the occurrence of complications were assessed using a log 
rank test. 
2.2.3 RESULTS 
Recruitment 
Between January and September 2013 all but 2 (one could not be reached, one had 
died) of the original 54 participants were contacted by telephone. Of the remaining 
52 original study entrants who were contacted 12 did not consent to the full 
cardiopulmonary exercise test protocol (the primary outcome), citing no time and the 
distance to their tertiary referral center as the main reason. Of these 12 patients, 3 
participated partly by filling out the quality of life questionnaires only. Consequently, 
40 patients completed the full cardiopulmonary exercise test protocol. Of these 40 
participants, 4 patients had not completed the full protocol in 2009. Consequently, 
22 patients who were originally assigned to the intervention group and 18 patients 
who were assigned to the control group were analyzed in the assessment of the 
primary endpoint. There were no differences in baseline parameters (age, Peak 
VO2, NT proBNP, medication, NYHA class) or event-rate between the 40 
participants of the current follow-up study and the 14 non-participants. In 50 of the 
original 54 participants medical charts with complete follow-up were available 
leaving 50 patients for survival analysis. 
Baseline data 
Table 1 outlines the baseline characteristics of all patients who participated in the 
follow-up analysis. The study groups were reasonably well balanced at the present 
re-evaluation, although patients with Senning operation were overrepresented in the 
intervention group, without reaching statistical significance. 
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Outcomes and estimations 
. Cardiopulmonary exercise testing 
In the overall group (n=40), Peak VO2 showed no significant change from baseline to 
three years of follow-up (−0.7 ml/kg/min 95% CI −2.6 ml/kg/min to 1.1 ml/kg/min, p= 
.43), nor were there significant changes in the two treatment groups (intervention 
0.1 ml/kg/min 95%, CI−2.7 ml/kg/min to 2.8 ml/kg/min, p=.96; control−1.6 ml/kg/min, 
95% CI −4.2 ml/kg/min to 0.9 ml/kg/min, p = .18). At three year follow-up, there were 
no differences in change in cardiopulmonary or hemodynamic parameters between 
the intervention and control groups (Table 2). A sensitivity analysis that included 
only patients who completed in the protocol in both 2009 and 2013 (control n=15, 
intervention n = 21) yielded similar results (Peak VO2 1.8 mg/kg/min (−1.8 
mg/kg/min to 5.5 mg/kg/min, p = .311)). 
. Sports habits 
Patients in the intervention group were not more likely to change their exercise 
habits than patients in the control group (increase in habitual exercise: intervention 
37% vs controls 24%, p = .38). 3.3.3. Serum N-terminal pro-hormone of brain 
natriuretic peptide There was no significant change from baseline in NT-proBNP. 
Moreover, at three year follow-up there was no effect of the ten week exercise 
program on serum NT-proBNP (Table 2).  
. Quality of life 
As can be seen in Table 2, no effect of the ten week exercise program on the quality 
of life-scores remained at three year follow-up. 
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. Ancillary analysis 
An exploratory univariate analysis of baseline characteristics yielded an association 
between change in exercise capacity and the use of β- blockers, RAAS inhibitors, 
and participation in sports. In multivariate analysis, RAAS inhibitors and sports 
participation remained independent predictors of change in exercise capacity at 
follow-up (Table 3).  
 
When compared to patients who did not exercise regularly (no sports group), 
patients who habitually exercised (sports group) had higher Peak VO2, although this 
effect was no longer significant when corrected for age and sex (Peak VO2 as 
percentage of predicted, Tables 4 and 5).  
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Sports participation at baseline was associated with an increase of 13% (95% CI 4% 
to 23%) of predicted Peak VO2 and a decrease of 62% (95% CI −115% to 10%) in 
NT-proBNP, when compared to patients who did not exercise (Table 5 and Fig. 2).  
	 20 
 
During follow-up 22 clinical events occurred in 13 patients (11 supraventricular 
arrhythmias, 4 episodes of worsening heart failure, 6 reoperations, 1 pulmonary 
embolism, 1 non-sustained VT and 1 sudden cardiac death). Whereas the 10-week 
exercise program had no effect on the occurrence of clinical events, patients in the 
sports group had better event-free survival than patients in the no-sports group (Fig. 
3).  
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2.3 EXERCISE CAPACITY IN CYANOTIC CONGENITAL HEART DISEASE 
Predicting survival of patients with cyanotic congenital heart disease: The value of 
cardiopulmonary exercise testing. Results from an international multicentre study. 
2.3.1 INTRODUCTION 
Patients with cyanotic congenital heart disease (CHD) are at risk of increased 
mortality. Few predictors of adverse outcome exist. Cardiopulmonary exercise 
testing (CPET) has been established as a prognostic tool in CHD patients – in 
general, but the value in cyanotic patients remains unclear. We analyzed the 
prognostic value of CPET in a large cohort of cyanotic patients. 
2.3.2 METHODS 
Cyanotic patients who underwent CPX at five major centres were included. 
Cyanosis was defined as oxygen saturation <90% during exercise or at rest. Cox 
proportional-hazards analyses were performed to identify predictors of all cause 
mortality. 
2.3.3 RESULTS 
582 patients were included (52% males, age 27.3±14.2 years, 39% cyanosis at 
rest). During a follow-up of 4.6 years, 69 patients died. Univariate predictors were 
older age (HR 1.25, p=0.003), NYHA-class >1 (HR 4.0, p=0.0002), lower peak VO2 
(HR 0.90, p<0.0001), lower anaerobic threshold (HR 0.90, p=0.0005), higher 
VE/VCO2 slope (HR 1.02, p<0.0001), lower resting O2-saturation (HR 0.95, 
p<0.0001), lower heart rate increase during exercise (HR 0.84 /10 bpm, p<0.0001), 
and lower O2-saturation during exercise (HR 0.97, p=0.0001). On multivariable 
analysis, peak VO2 was the only significant predictor (HR 0.88, p<0.0001). The 
figure below shows survival by quartiles of peak VO2. 
In patients with resting cyanosis, lower peak VO2 (HR 0.92, p=0.002), higher 
VE/VCO2-slope (HR 1.02, p=0.01), lower anaerobic threshold (HR 0.90, p=0.02) and 
lower heart rate increase (HR 0.82 /10 bpm, p=0.001) were predictive. On 
multivariable analysis lower peak VO2 was the only predictor. 
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2.4 EXERCISE CAPACITY IN UNIVENTRICULAR PHYSIOLOGY 
Children born with a single ventricle represent 2% of patients with congenital heart 
disease. Single ventricle hearts comprise a heterogeneous group of defects which 
are not suited for a two ventricle repair. Since 1971 they have been palliated with a 
Fontan operation and subsequent modifications 62,63. Patients with a total cavo-
pulmonary connection can nowadays look forward to significantly improved life 
expentancy, exercise tolerance and quality of life, still they face impaired physical 
capacity and increased mortality compared to their peer 63.  
 
Previous studies suggested that exercise intolerance is a powerful prognostic 
marker in patients with CHD establishing an association between exercise 
intolerance and increased morbidity and mortality 64. Among the different screening 
tools employed during periodic follow-up, cardiopulmonary exercise testing (CPET) 
has emerged as one of the most valuable. It is non-invasive, enables risk 
stratification with regard to morbidity and mortality, and helps deciding on the need 
and timing of therapeutic interventions 65. Patients with a Fontan circulation exhibit a 
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novel and unique artificial phisiology both at rest and on exerction, which is 
considered responsible for the 30% to 40% lower exercise tolerance than that of 
healthy, age-matched controls 66. A number of different exercise test parameters 
have been used to try and predict outcome or to better evaluate exercise capacity in 
this population. It can be difficult to obtain maximal exercise levels, both for intrinsic 
physiological reasons and the specific population young age, which often prevents 
them to be fully cooperating.  For this reason some groups concentrated their work 
on submaximal parameters 67, nonetheless some that proved useful in adult 
populations with acquired cardiac disease are not reliable for evaluation in the 
Fontan circulation 68. Of particular concern is that exercise capacity seems to further 
lower during follow-up 69. 
2.4.1 EXERCISE CAPACITY IN UNIVENTRICULAR PALLIATION: 
METAREGRESSION OF PREVIOUS STUDIES 
2.4.1.1 SEARCH STRATEGY 
A literature search on the Medline database covering from 1971 to January 2014 
was performed. Serch terms used were “Fontan” OR “univentricular heart” AND 
“exercise” OR “exercise testing” OR “exercise capacity” OR “exercise tolerance” 
(349 papers). The search was performed by one of the authors. The abstracts of 
relevant articles were screened on the basis of the following criteria: the study 
population or part of the study population had to have a Fontan circulation and 
exercise testing had to be a CPET (cycloergometry or treadmill test with gas 
exchange evaluation). If data reported in the abstract met the inclusion criteria, the 
full-text paper was studied. References of the selected publications were tracked to 
find additional publications on this subject. 
To be included in our analysis publications had to include a description of the 
patients characteristics (at least mean age at CPET and gender) and exercise 
stress test variables (VO2 max in mL/min/kg or percent of predicted VO2 max value 
for age and sex). Where feasible we asked the authors for missing data. This left us 
with 123 papers that matched our criteria. When more than one paper was reported 
from the same exercise laboratory we chose either the latest or the largest which 
satisfied the criteria. Exceptions were made when different papers from the same 
center described patients that were not included in the previously reported cohorts. 
We excluded from our analysis cohort consisting of 10 patients or less. A flow-chart 
of the search strategy and result is shown in figure 1. 
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Figure 1. Flowchart of the search strategy 
2.4.1.2 RESULTS 
We considered for our meta-regression analysis a total of 39 papers shown in table 
1 70-108. 
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Table 1. Type of exercise: C: cycloergometer; T: treadmill. RER: respiratory 
exchange ratio (if mentioned in the paper). Diagnosis: All: mixed diagnosis; LV: 
univentricualar heart with left morphology; RV: univentricualr heart with right 
morphology; TA: tricuspid atresia. TCPC: total cavopulmonary connection. ECC: 
extracardiac conduit. Fen: patent fenestration at time of CPET (if mentioned in the 
paper or provided by the author). peak VO2%: percent of predicted VO2. HR: heart 
rate. WL: workload. HRR: heart rate reserve (peak HR-rest HR). VE/VCO2: 
ventilatory equivalent  for carbon dioxide; *:slope; °: ratio. 
 
Our analysis considered a total of 2247 patients, data come from a broad time 
window and this gives reason for the different surgical approach (classic Fontan, 
intra-atrial tunnel, extracardiac conduit) and age at final palliation.  
Meta-regression analysis was performed on VO2 max in mL/min/kg or percent of 
predicted VO2 max value for age and sex or both depending an data provided by the 
authors and results are shown in the figure below. 
 
 
It is clearly shown that peak VO2, either considering absolute and percent of 
predicted values, declines with age. This is consistent with what Anderson et al. 109 
and Fernandes et al. 110 previously reported in smaller cohorts. In the vast 
population considered this trend is well-rendered despite surgical tecniques 
improvements over the last three decades. 
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2.4.2 ANALYSIS OF EXERCISE TOLERANCE IN A LARGE FONTAN 
POPULATION 
2.4.2.1 METHODS 
Data for analyses described here were obtained from the two largest databases on 
exercise tolerance in patients with a Fontan circulation. The NIH/NHLBI Pediatric 
Heart Network Fontan Cross-Sectional Study dataset was used in peparation of this 
work together with the dataset of patients analysed by Diller and colleagues 65, 111. 
Data were downloaded from 
https://pediatricheartnetwork.com/pud_login.asp?study_id=FSCD. Subjects in this 
study were survivors of multistage surgical palliation for functional single ventricle 
ending with a Fontan procedure. Periodic exercise testing is standard for Fontan 
patients capable of performing CPET at the institutions involved. 
. Cardiopulmonary exercise test 
Exercise tests were performed on an electronically braked cycloergometer or on a 
treadmill. Carbon dioxide elimination, VO2, and minute ventilation were measured 
with a computerized breath-by-breath analyser. Patients performed a symptom-
limited maximal exercise test using an incremental protocol that allowed reaching 
exhaustion in ≈10 min of exercise. A 12-lead electrocardiogram and transcutaneous 
oxygen saturation were also continuously monitored throughout the study, and blood 
pressure was determined manually every 2 min. The technical details of 
measurement of peak VO2 and VE/VCO2-slope have been published 69, 112,113. 
Resting heart rate was measured after at least 2 min of complete rest in a seated 
position, whereas peak heart rate was defined as the maximal heart rate achieved 
during exercise. Heart rate reserve was calculated as the difference between peak 
and resting heart rates 64. Standard equations were used to generate predicted 
values for peak exercise parameters 114. Because of age-related differences of 
normal peak VO2 when expressed in mL/ kg/min, peak VO2 was also expressed as 
% of predicted value 115. Anaerobic threshold was determined according to Beaver 
et al 116. 
. Statistical Analysis 
Continuous variables are summarized by mean±standard deviation or median and 
interquartile range, depending on normality of distribution. Categorical variables are 
represented by frequen- cies and percentages. Wilcoxon rank sum tests and χ-
squared tests were used, as appropriate, to compare clinical and demographic 
features of patients . T-tests were used to test for differences in mean CPET 
parameters between groups. Statistical significance was achieved with a two-sided 
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P-value < 0.05. All analyses were performed using SPSS, Version 22 for Mac 
(SPSSStatystics software, IBM/   SPSS, Inc., Chicago, IL, USA). 
2.4.2.2.RESULTS 
A total of 732 Fontan patients who underwent CPET were identified. From this 
population we excluded CPET performed on a treadmill (85 patients) to exclude 
variabilities due to differences in the test methodology. 
Our cohort consisted of 647 patients who performed the CPET on a cycloergometer. 
Among those we chose to study those who achieved maximal effort, considered to 
be RER≥1.09 at peak exercise. Details of the 301 patients (41.2% of the initial 
cohort) that performed a maximal effort cicloergometer CPET are shown in table 2. 
171 patients were male (56.8%), the patients’ median age at the time of CPET was 
15.4 years (range 7.2-44.8, IQR 12.5– 18.1). Ventricle morphology was left in 218 
(72.4%), Fontan type is shown in table 2. 
 
 
All patients Maximal effort  
Sub 
Maximal 
effort  
p 
value 
Patients no. 647 301 346 - 
Age at evaluation (years) median 13.6 
10.5-17.3 
15.4 
12.5-18.1 
11.6 0.000* 
IQR 9.5-15.5 
Gender (male)  379 (58.6%) 171 (56.8%) 208 (60.1%) 0.378⌃ 
Age at Fontan (years) median 3.4 
2.3-5.5 
3.4 
2.3-5.7 
3.4 0.845* 
IQR 2.3-5.4 
Time since Fontan (years) mean±
SD 9.5±4.8 11.1±4.6 8.2±4.5 
0.000° 
LV morphology 465 (71.9%) 218 (72.4%) 247 (71.4%) 0.762⌃ 
Surgery palliation classic/modified 
Fontan 156 (24.1%) 85 (28.2%) 71 (20.5%) 0.352⌃ 
lateral tunnel 
TCPC  
ECC TCPC  
350 (54.1%) 
141 (40.6%) 
157 (52.2%) 
59 (19.6%) 
193 (55.8%) 
82 (23.7%) 
0.403⌃ 
0.223⌃ 
Pacemaker 65 (10.1%) 36 (12%) 29 (8.4%) 0.134⌃ 
Table 2. clinical details of the whole cohort and comparison between the maximal 
and sub-maximal effort subgroups. TCPC: total cavo-pulmonary connection; ECC: 
extracardiac conduit. *: Mann-Whitney U test; °: Independent samples T test; ⌃: 
Pearson χ-squared. 
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The peak VO2 in the whole population was 25.2±7.3 mL/kg/min, 60.7±19.9%  and in 
the maximal effort group was 26.3±6.9 mL/kg/min, 63.3±17.1% predicted. 
 All patients Maximal effort Sub Maximal effort p value 
Patients no. 647 301 346 - 
Resting HR (bpm) mean±SD 81±17 80±18 82±17 0.154° 
Resting SatO2 (%) mean±SD 92.7±10.6 93.1±8.5 92.3±12.2 0.369° 
Resting SBP (mmHg) mean±SD 106±14 108±14 104±14 0.000° 
FEV1 (L) median 1.93 
1.43-2.56 
2.26 
1.75-2.97 
1.73 
1.27-2.20 
0.000* 
IQR 
FVC (L) median 2.23 
1.62-2.99 
2.59 
2.04-3.41 
1.85 
1.38-2.53 
0.000* 
IQR 
MVV (L/min) mean±SD 62.9±30.8 74.0±33.7 54.0±24.9 0.000° 
AT VO2 (mL/kg/min) mean±SD 17.5±6.2 17.6±5.8 17.6±6.7 0.048° 
Peak VO2 (mL/kg/min) mean±SD 25.2±7.3 26.3±6.9 24.2±7.5 0.000° 
Peak VO2  
(% of predicted value) 
mean±SD 60.7±19.9 63.3±17.1 58.4±21.8 0.002° 
HRR (bpm) mean±SD 71±31 79±32 65±29 0.000° 
Peak HR (bpm) mean±SD 149±29 154±24 147±27 0.001° 
Peak SatO2 (%) mean±SD 83.9±23.8 87.7±16.1 83.2±25.6 0.012° 
Peak SBP (mmHg) mean±SD 132±31 142±24 134±23 0.000° 
Peak RER mean±SD 1.06±0.10 
0.66-1.37 
1.15±0.05 
1.09-1.37 
0.95±0.19 - 
 min-max 0.66-1.08 
Peak workload (watts)  mean±SD 80.7±41.0 99.7±43.0 64.8±29.2 0.000° 
peak VE/VCO2 ratio   mean±SD 44.5±9.9 
(403pts) 
43.0±8.5 
(188pts) 
45.8±10.6 
(215 pts) 0.013° 
Table 3. CPET parameters of the whole cohort and comparison between the 
maximal and sub-maximal effort subgroups. HR: heart rate; SatO2: oxigen 
saturation; SBP: systolic blood pressure; FEV1: forced expiratory volume; FVC: 
forced vital capacity; MVV: Maximal Voluntary Ventilation; AT: aerobic threashold; 
VO2: oxygen consumption; HRR: heart rate reserve; RER: respiratory exchange 
ratio; VE/VCO2: ventilatory equivalent ratio for carbon dioxide. *: Mann-Whitney U 
test; °: Independent samples T test. 
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2.5 EXERCISE CAPACITY IN PAEDIATRIC DILATED CARDIOMYOPATHY 
2.5.1 BACKGROUND 
Dilated cardiomyopathy (DCM) is the final common phenotypic pathway for multiple 
pathological processes that are characterized by left ventricular (LV) chamber 
dilation and systolic dysfunction, and clinically manifested by congestive heart 
failure 117. 
Etiologies may include antecedent viral myocarditis and generalized myopathies, 
along with a broad spectrum of sarcomeric, sarcolemmal, cytoskeletal, or nuclear 
protein abnormalities. However, etiology remains idiopathic in approximately two-
thirds of cases 118. Epidemiological studies have estimated the incidence of newly 
diagnosed DCM to be between 0.57 and 0.73 cases per 100,000 per year among 
infants and children <18 years of age 119,120. Despite advances in the medical 
management of congestive heart failure, the prognosis of children with DCM 
remains poor, with a 5-year transplantation-free survival of approximately 50% 121. 
Conventionally, maximal oxygen uptake (peak VO2), assessed during 
cardiopulmonary exercise testing (CPET), has been used for risk stratification in HF 
patients with non-ischemic DC 117. The clinical management of outpatient children 
with heart failure secondary to dilated cardiomyopathy (DCM) has been greatly 
improved by the routine monitoring of biomarkers (natriuretic peptides) and exercise 
tolerance (cardiopulmonary exercise test, CPET). They offer useful advice in 
monitoring the progression of the disease. The aim of the study was to determine 
their usefulness in the timing for transplant listing in the paediatric population and 
their potential value as predictors of outcome (death and transplant) in outpatient 
children with DCM. 
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2.5.2 METHODS 
This study was designed as single-center and retrospective, the need for consent 
was waived due to the study design. DCM was diagnosed based on 2006 definitions 
and classification of cardiomyopathies by the American Heart Association. 
DCM was defined as left ventricular end-diastolic diameter Z score -2.0 and a left 
ventricular shortening fraction (LVSF) <30%. Fourty-eight patients were enrolled in 
this study according to the inclusion criteria: (1) paediatric DCM patients aged <18 
years, (2) availability of complete data for serial measurements of NT-proBNP and 
exercise test, and (3) a follow-up duration >6 months.  
All children enrolled were outpatients and considered stable on oral medical therapy 
alone. None had been hospitalized in the month before assessment. Their clinical 
assessment included physiological data, medications prescribed, echocardiography. 
All children at least 120 cm tall and able to exercise on a bicycle underwent a 
cardiopulmonary exercise test as part of their functional capacity. Serum 
biomarkers, first available at our institution as BNP and later as NT pro-BNP, were 
requested when signs and symptoms of worsening heart failure manifested despite 
medical therapy, with clinical suggestion of deterioration and progression to medical 
refractory decompensation requiring assessment for non medical management. 
Most of the investigations were performed on the same date, when that was not 
possible sets of investigations performed within 6 months have been considered. 
. Follow-Up and Survival  
Al the children enrolled have remained under continued clinical follow up at our 
institution, so that all events in the cohort were captured. 
Medical records were reviewed to obtain relevant data, including survival status. 
Survival was taken as the time from initial exercise testing. The study end point was 
the combination of death and transplant, where criteria for elective listing were 
based on the presence and magnitude of symptoms and deteriorationd espite 
optimal medical therapy. Criteria for urgent listing were mechanical ventilation, high-
dose intravenous inotropic agents, or need for bridging with an extracorporeal 
membrane oxygenator or ventricular assist device. 
. Echocardiography 
Echocardiography was performed using a GE Vivid series (General Electric 
Healyhcare, Buckingamshire, UK). In the echocardiographic data, we investigated 
left ventricular (LV) diastolic dimension, LV systolic dimension, LV ejection fraction 
(EF), and LV fractional shortening (FS. M-mode measurements for LV diastolic 
dimension, LV systolic dimension, LVEF, and LVFS were obtained from the 
parasternal long-axis view. Body surface area normalized z scores for LV systolic 
dimension and LV diastolic dimension were then calculated 122,123. Although 
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extrapolation of EF from linear LV minor-axis diameters can be inaccurate because 
of the geometric assumptions 124, acceptable ventricular geometry was observed 
supporting the linear relation between LVFS and LVEF based on volumetric 
measurements. Because of incomplete data on LVEF, LVFS was consistently used 
instead.  
. Cardiopulmonary Exercise Test 
Exercise tests were performed on an electronically braked cycloergometer. Carbon 
dioxide elimination (VCO2), VO2 and minute ventilation (VE) were measured with a 
computerized breath-by-breath analyzer (Medgraphics, St. Paul, MN). Patients 
performed a symptom-limited maximal exercise test using a continuous incremental 
bicycle protocol with a work rate increment between 5 and 20 W/min, with the aim of 
completing the test within 10 to 12 minutes of exercise. Criterion for test ending was 
considered patient exhaustion with a respiratory exchange ratio >1.09. A 12-lead 
ECG and transcutaneous oxygen saturation were also monitored continuously 
throughout the study, and cuff blood pressure was determined manually every 2 
minutes. Resting heart rate (HR) was measured after at least 2 minutes of complete 
rest in a seated position, and peak HR was defined as the maximal HR achieved 
during exercise. Predicted maximum HR was estimated according to the following 
formula: 200-age in years 125. Chronotropic incompetence was described as a ratio 
of peak HR to predicted peak HR of <0.85 126. None of the patients had known 
coronary artery disease or inability to exercise for other reasons. Standard 
equations were used to generate predicted values for baseline spirometric and peak 
exercise parameters 115. Because of age-related differences in normal peak VO2 
when expressed in milliliters per kilogram per minute in a pediatric patient cohort 
with a large age range, peak VO2 was expressed as percent of predicted value 
based on sex and age 127. Z scores for peak exercise systolic blood pressure were 
calculated from the normative dataof Alpert et al. 128. 
. Biomarkers 
BNP and NT pro-BNP samples were all obtained by venipuncture and processed by 
our biochemistry laboratory. 
BNP measurements were carried out on a point of care on blood samples collected 
in EDTA tubes with a fluroescence immunoassay (Triage Meter, Biosite). Scarce 
data is available in literature on normal values in children, we used the cut off 
suggested by Koch and Singer 129. 
NT pro-BNP measurements were performed on heparinised plasma with a 
chemillumiscent immunoassay (IMMULITE 2000 NTproBNP, Siemens). Our 
laboratory validated the reference values in children that we are currently using 130. 
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For both biomarkers it is recognised normal values vary impressively in children 
being extremely high in neonates, decreasing rapidly in the first weeks of life to then 
normalise and stabilise to adult values at puberty. 
. Statistical Analysis 
Data distribution was tested for normality with the Shapiro-Wilk test. Normally 
distributed continuous variables data are reported as mean±standard deviation, not 
normally distributed continuous variables as median (25° percentile-75° percentile). 
Categorical variables are reported as number and percentage. Patients were divided 
into two groups depening on their clinical outcome. Patients who died during follow 
up or underwent urgent or elective orthotopic heart transplant were grouped in the 
“Events” group. Patient who were alive with no transplant at their last follow up are 
described in the “No events” group. 
The two groups were compared for differences on major demographic, 
echocardiographic, exercise parameters and biomarkers using independent 
samples T-test, Mann-Whitney U test and Pearson’s χ2 test as appropriate.  A 2-
tailed value of p≤0.05 was used as the criterion for statistical significance. 
Kaplan-Meier curves were plotted for all events (death and transplant) and groups 
were compared. First grouping variable was biomarkers (normal vs. abnormal 
values), then an empirical cutoff value of peak VO2 (62%) was selected to define 
groups 145. 
All analyses were performed using SPSS, Version 22 for Mac (SPSSStatystics 
software, IBM/  SPSS, Inc., Chicago, IL, USA). 
2.5.3 RESULTS 
Between 2003 and 2013 we enrolled 48 consecutive patients with DCM in this 
study, the baseline characteristics are presented in Table 1. DCM was idiopathic in 
37 (77.1%), induced by anthracycline in 5 (10.4%), and secondary to Duchenne 
muscular dystrophy in 1 (2.1%), mitochondrial disease in 1 (2.1%) and post-
myocarditis in 1 (2.1%). 
All children completed a symptom-limited CPET at a mean age of 14.2±2.1 years 
(range 9.4-17.9 years), with a peak exercise respiratory exchange ratio of 1.12 ±0.8. 
Overall, LVSF was 17.9±7.2%. Exercise capacity was 24.9±10.3 mL/kg/min (range 
11.1-46.9 mL/kg/min), which corresponded to 65.8% of predicted (IQR 39.5%-
86.9% and range 30.7%-108.9%). Peak HR in the overall study cohort was 
155.6±22.5 bpm (range, 114–207 bpm), which corresponded to 83.8±12.2% of 
predicted (range, 60.7%–111.5%). Peak exercise systolic blood pressure was 120 
mmHg (IQR 100-130), with Z-score of -4.4±3.5. Twenty-eight patients (58.3%) had 
chronotropic incompetence. Biomarkers were tested in all the patients: twenty-seven 
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patients had BNP tested and this was 346.9±470.4 pg/mL (range 4-1580 pg/mL), 21 
patients had NT pro-BNP measured and this was 3537.6±5367.3 pg/mL  (range 24-
21784 pg/mL). 
Thirty patients (62.5%) were receiving β-blockers at the time of the CPET, and 
fourty patients (83.3%) were receiving angiotensin-converting enzyme inhibitors. All 
children were in sinus rhythm with 5 patients on antiarrhyrtmic prophylaxis. 
 
Variable Overall Study Cohort 
(n=48) 
Etiology, n (%)  
idiopathic 31 (64.6) 
familial 6 (12.5) 
anthracyclines induced 5 (10.4) 
DMD 1 (2.1) 
mithocondrial 1 (2.1) 
post-myocarditis 1 (2.1) 
Age at CPET, y 14.2±2.1 
Male sex, n (%) 29 (60.4) 
Weight, kg 55.4 (44.0-67.3) 
Body surface area, m2 1.58±0.31 
Body mass index, kg/m2 20.0 (17.8-23.4) 
LVSF, % 17.9±7.2 
Peak workload, W 103.0 (69.3-140.5) 
Peak SPB, mmHg 120 (100-130) 
z score -4.4±3.5 
Peak heart rate, bpm 155.6±22.5 
% of predicted 83.8±12.2 
Prevalence of chronotropic incompetence, n 
(%) 
28 (58.3) 
Peak VO2, mL/kg/min 24.9±10.3 
% of predicted 65.8 (39.5-86.9) 
VE/VCO2 slope 31.1 (26.2-35.1) 
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Peak respiratory exchange ratio 1.12 ±0.8 
BNP, pg/mL (27 pts) 346.9±470.4 
NT pro-BNP, pg/mL (21 pts) 3537.6±5367.3 
Medications, n(%)  
Diuretics 25 (52.1) 
K-sparing diuretics 13 (27.1) 
β-blockers 30 (62.5) 
ACE-inhibitors 40 (83.3) 
Digoxin 16 (33.3) 
Amiodarone 5 (10.4) 
Aspirin 16 (33.3) 
Warfarin 13 (27.1) 
DMD: Duchenne muscular dystrophy; CPET: cardiopulmonary exercise test; LVSF: 
left ventricular shortening fraction; SBP systolic blood pressure; VO2 oxygen uptake; 
VE/VCO2 ventilatory efficiency; BNP: brain natriuretic peptide; NT pro-BNP: amino-
terminal of the prohormone brain natriuretic peptide 
. Outcome 
All patients had complete follow-up until December 2014. At an average follow-up 
(time from CPET to first event) of 14.2±18.5 months (range, 0.3 [early 
transplantation] to 83.4 months), 25 patients reached the end point of death or heart 
transplant. In detail, 7 patients died (1 died after heart transplant and 1 on the list), 
19 patients were listed for transplant either electively (12) or needed urgent listing 
(7) because of severe clinical deterioration and were bridged to HTx on high-dose 
intravenous inotropic support ventricular asiistance/ECMO.  
 
At univariate analysis echocardiographic and exercise parameters, biomarkers and 
use of diuretics and ACE-i were all associated with a higher rate of death or need for 
HTx, whereas sex, age at CPX and body size were not.  
In the multivariable analysis that included peak VO2% and LVSF as independent 
variables  peak VO2% was the only variable associated with the composite end 
point. Kaplan-Meier curves plotted for abnormality of biomarkers values (BNP and 
NT pro-BNP) showed none of the children with normal biomarkes died or were listed 
for urgent HTx. Using the empirical peak VO2 cutoff point of 62% of predicted, 
Kaplan-Meier survival curves showed a higher rate of death/listing for urgent HTx in 
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patients with a peak VO2 62%. Kaplan-Meier curves are also showns for the 
composte end point comprisig all events (death, urgent and elective HTx). 
 
Variable No events 
(n=23) 
Events 
(n=25) 
p 
Age at CPET, y 14.6±2.3 13.9±1.8 0.222* 
Male sex, n (%) 13 (57) 16 (64) 0.597⌃ 
Height, cm 162.0±16.0 159.1±12.9 0.505* 
Weight, kg 57.8 
(42.5-73.7) 
50.0  
(44.0-64.8) 
0.358° 
Body surface area, m2 1.62±0.36 1.53±0.27 0.328* 
Body mass index, kg/m2 20.9 
(17.9-24.5) 
19.9 
(18.1-22.2) 
0.516° 
LVSF, % 22.5±5.7 13.6±5.7 0.000* 
LVEDD, mm 57.7±10.5 68.3±9.9 0.001* 
LVEDD/BSA, mm/m2 36.6±7.6 45.5±7.8 0.000* 
LVESD, mm 45.1±10.3 58.5±9.2 0.000* 
LVESD/BSA, mm/m2 28.4±6.5 39.0±8.0 0.000* 
Peak workload, W 133.0 
(100.5-153.5) 
80.0 
(57.0-108.0) 
0.002° 
Peak SPB, mmHg 128 
(120-142) 
104 
(94-118) 
0.000° 
z score -2.3±2.6 -6.3±3.1 0.000* 
Peak heart rate, bpm 165.2±23.0 146.7±18.3 0.004* 
% of predicted 89.1±12.4 78.8±10.0 0.003* 
Peak VO2, mL/kg/min 29.8±11.3 20.4±6.8 0.001* 
% of predicted 76.4 
(65.2-104.4) 
54.9 
(32.7-73.1) 
0.001° 
VE/VCO2 slope 27.9 
(25.6-29.8) 
32.5 
(31.1-37.2) 
0.001° 
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BNP, pg/mL (27 pts) (n=13) 
11.2 
(6.5-26.4) 
(n=14) 
496.0 
(301.8-1013.0) 
0.000° 
NT pro-BNP, pg/mL (21 pts) (n=10) 
118.5 
(62.8-581.5) 
(n=11) 
4754.0 
(2525.5-5844.5) 
0.000° 
Abnormal biomarkers, xULN 0.5 
(6.5-26.4) 
19.2 
(12.1-34.6) 
0.000° 
Medications, n(%)    
Diuretics 6 (23.1) 19 (76.0) 0.001⌃ 
K-sparing diuretics 4 (17.4) 9 (36.0) 0.147⌃ 
β-blockers 13 (56.5) 17 (68.0) 0.412⌃ 
ACE-inhibitors 16 (69.6) 24 (96.0) 0.014⌃ 
Digoxin 5 (21.7) 11 (44.0) 0.102⌃ 
Amiodarone 2 (8.7) 3 (12.0) 0.708⌃ 
Aspirin 6 (26.1) 10 (40.0) 0.307⌃ 
Warfarin 3 (13.0) 10 (40.0) 0.036⌃ 
*: independent samples T-test; °: Mann-Whitney U test; ⌃: Pearson’s χ-squared test 
Univariate analysis for patients reaching endpoint (death or heart transplant, urgent 
or elective) during the study.  
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We also grouped biomarkers, peak V02 and VE/VC02 slope in tertiles and tested 
their concordance in predicting potcomes. The results are shown in the tables below 
and plot biomarkers against CPET parameters separately to assess the while 
children with normal biomarkers had no events peak V02 was in the upper tertile 
(>76.4%) in 5 children who had a negative outcome, nonetheless concordance of 
the two (i.e. normal biomarkers and high peak V02 or severly abnormal biomarkers 
and peak V02) was effective in predicting outcome. The same considerations apply 
to the comparison between biomarkers and VE/VC02 slope underlying how better 
prediction of outcome is possible when the two tests are assessed together as 
compared to using exercise test alone. Biomarkers showed excellent predictive 
value even when considered alone with no events in children with biomarkers in the 
lower tertile and adverse outcome in all the patients with biomarkers in the higher 
tertile. 
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Kaplan-Meier for death/urgent Htx according to abnormal biomarkers  
 
Kaplan-Meier for death/urgent and elective Htx according to abnormal biomarkers 
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Kaplan-Meier for death/urgent Htx according to peak V02> 62%
  
Kaplan-Meier for death/urgent and elective Htx according to peak V02> 62% 
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3. FUTURE PERSPECTIVES 
3.1 SKELETAL AND RESPIRATORY MUSCLE TRAINING IN TCPC 
PATIENTS  
Patients with congenital heart defects present with reduced exercise capacity and 
this has prognostic implications. 
Reduced exercise capacity is multifactorial in this group and mainly related to 
abnormal cardiovascular haemodynamics during exercise (inappropriate increase in 
stroke volume or heart rate to exercise), abnormal perfusion of the exercising 
muscles, abnormal extraction of O2 from the exercise muscles, and abnormal O2 
content (hypoxemia or anemia). 
There is evidence that patients with CHD have reduced skeletal and respiratory 
muscle strength, as assessed by maximal inspiratory and expiratory pressures at 
rest and 10 minutes after maximal exercise. This evidence exists for patients with 
repaired tetralogy of Fallot, Fontan operation and Mustard/Senning operation. 
Reduced respiratory muscle strength can be important in patients with CHD for 
several reasons: 
1) Patients with CHD need to hyperventilate during exercise because of 
hyperstimulation form chemo and metaboreceptors, with potential for 
premature interruption of exercise because of dyspnoea (high Borg scale). 
2) Hyperventilation is particularly increased in patients with hypoxemia 
(Eisenmenger, Fontan) 
3) Respiratory muscle fatigue related to reduced respiratory muscle strength 
causes an increase in adrenergic stimulation, which produces a 
vasocostriction in the skleletal muscles arteries, compromising perfusion of 
exercising muscles (quadriceps in bicycle ergometry). 
4) Some patients, like those with TCPC heavily rely on ventilation (and therefore 
respiratory muscle stranght and their tolerance to progressive exercise) to 
increase their cardiac output during exercise. 
 
Studies in adults with heart failure have shown that respiratory muscle training can 
improve exercise tolerance and peak VO2, by means which differ from those of 
standard aerobic exercise training. 
Skeletal muscle deconditioning have an additional role in decreased exercise 
capacity and patients with CHD are frequently discouraged from participating in any 
kind of physical activities for social/psychological reasons in fear of increased risk of 
adverse events. Recently a relevant body of literature has become available to 
confirm these patients, even with complex conditions palliated with univentricular 
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circulation, are safe in undertaking mild to moderate aerobic exercise and evidence 
is emerging regarding the benefit of regular training in their overall health and 
prognosis. 
We are recruiting teenager patients with univentricular physiology in two pilot studies 
regarding exerxise training, one is focusing on skeletal muscle training with a 
computer based exercise programme (Nintendo Wii) and the second focuses on 
respiratory muscles training. 
3.2 MULTISCALE MODELLING OF UNIVENTRICULAR HEARTS 
Developed in the 1930s and 1940s to study hydraulic problems, computational fluid 
dynamics (CFD) has become a practical modelling tool to solve and analyse 
physical phenomena that involve fluid flows. In congenital cardiac surgery, where 
the objective of the operative reconstruction is to reshape the blood flow within the 
heart and great vessels to achieve the best dynamics and tissue oxygen delivery, 
CFD is a natural tool to uncover suboptimal circulations and improve surgical 
techniques. However, a lack of a common language and mutual understanding of 
each other's expertise have often stymied this logical collaboration between cardiac 
surgeons and engineers. Advances in computational methods have led to numerous 
contributions in the field of congenital heart diseases and surgery, including assist 
device development, studying of valvular and aortic pathologies, modifications to the 
Fontan operation and the continuing efforts to understand the modified physiologies 
in single ventricular circulations. 
While these advances have shed light into some of the altered flow dynamic 
phenomena that are unique in congenital heart surgery, there has been an 
increased recognition that modelling approaches that only focus on the local or the 
surgical domain will miss or underrepresent the overall effects on the entire 
cardiovascular and pulmonary physiology. In effect, the haemodynamics of the 
operative reconstruction site are dynamically coupled to the rest of the 
cardiovascular system. New multiscale modelling methods have been developed to 
provide a computationally efficient approach to correctly model both local and 
systems-level behaviour. Without going into the mathematical background, a 
multiscale model of the cardiovascular system combines the detailed 3D, 
anatomically accurate CFD model of the desired surgical reconstruction with a zero-
dimensional (0D) hydraulic lumped-parameter network (LPN) representation of the 
rest of the cardiovascular circulation system. Computationally, the flow and pressure 
output values from the 3D CFD model become the input pressure and flow values to 
the 0D LPN and, in turn, these same outputs from the LPN model become the input 
values to the CFD model of the surgical domain. This multiscale approach, such as 
shown for a TCPC model (Fig. 1), allows for closed-loop circulatory modelling. The 
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initiating conditions set by the user put into motion a set of calculations that 
iteratively arrive at flow and pressure solutions anywhere in the circulation. In a 
multiscale TCPC model, not only would shear stress and power loss within the 
TCPC be calculated, but also would a host of clinically relevant physiological 
variables, such as Fontan pressures, pressure–volume relationship of the single 
ventricle and cerebral perfusion. And when combined with fundamental oxygen 
equations, systemic and end organ, such as cerebral and myocardial, oxygen 
delivery can be assessed. Further adjustments to these models allow for simulations 
under exercise and growth effects. The aim is to establish a new investigative 
paradigm in which patient-specific anatomy and physiology are used in an 
engineering model to predict surgical outcomes, better understand hamodynamic 
changes related to the physiological changes induced by exercise and supplement 
patient management. Such a process involves virtual surgery and 
computational/experimental simulations using clinical data acquired from 
echocardiography, computed tomography, magnetic resonance imaging and cardiac 
catheterization. Multiscale models were constructed to assess the surgically altered 
flow dynamics, as well as the overall physiological effect in a clinically relevant 
manner. 
We are currently working on projects that aim to explore the importance of 
anatomical shape in determing the heamodynamic efficiency of the circuit, in 
particular the aortic arch shape after Norwood reconstruction and the pulmonary 
artery anatomy. Furthermore we are implementing LPN models to predict 
physiological response of the TCPC circuit in conditions that require increase in 
cardiac output and namenly exercise and pregnancy. Both this physiological 
changes in TCPC pose great difficulties to clinicians. Major differences can be 
observed from in response to exercise as outlined previously and poor outcome is 
well recognised in pregnancy in this cohort with very high rate of miscarriages, low 
birth weight and prematurity. We hope further development of these computational 
models will shed some light on our understanding of this artificial physiology. 
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Multiscale model coupling a patient-specific, realistic 3D extracardiac conduit total 
cavopulmonary connection with the 0D hydraulic lumped parameter network of 
entire cardiovascular system, including a single-ventricle heart and pulmonary 
circulation. 
4. DISCUSSION  
4.1 EXERCISE CAPACITY IN LEFT TO RIGHT SHUNTS 
Patients with significant left-to-right shunt, particularly ASD patients, even if 
asymptomatic, have a significant exercise capacity limitation when compared to 
healthy controls. Patients who are symptomatic, those with larger shunts and those 
with increased pulmonary artery pressure can be particularly limited. Patients with 
ASD, like many other children with congenital heart defects, generally adapt to their 
limitation which is present since early infancy and describe themselves as 
asymptomatic, even when their exercise capacity is clearly reduced 37,53,131. 
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Therefore, indication for closure can not rely on symptoms which are generally late, 
when complications have already developing. There are no available longitudinal 
data on exercise capacity in untreated ASD patients but early cross-sectional 
evaluations suggested symptoms usually develop during adulthood and the natural 
history of the disease is not benign in the long term 27. While we agree on ASD 
closure when a large shunt is detected during childhood, debate is still ongoing in 
older patients with smaller shunts or large shunts that eventually caused borderline 
pulmonary vascular damage with slight and/or reversible raise in pulmonary arterial 
pressures. Age does not seem a determinant of the response to ASD closure as 
over 40 years old seem to improve their peak VO2 in a similar fashion to those 
patients below 40 years of age 27,28. Even though there is an association between 
change in peak VO2 and size of the left-to-right shunt, patients with smaller shunts 
(like those with a Qp/Qs <2) also show some clinically significant improvements in 
their exercise capacity after closure. After surgical closure right ventricular 
dimensions change dramatically and exercise capacity greatly improves. However, 
whereas in children exercise capacity gradually reaches normal values in the long 
term 31, peak VO2 fails to reach predicted values in adult patients with preoperative 
signs of pulmonary hypertension 44. Due to its less invasive nature with short 
recovery time and low morbidity and mortality, percutaneous closure has becoming 
the first choice treatment in older children and adults with a suitable anatomy. The 
first small studies on trans-catheter closure showed no significant difference in peak 
VO2 after closure 33,34. Larger subsequent studies showed that percutaneous ASD 
closure led to an improvement in exercise capacity regardless of age at ASD closure 
45 and symptoms, but proportional to the amount of left-to-right shunt and pulmonary 
artery pressure 35,43. Data from our lab 37 have shown that the left to right shunting of 
blood does not only cause pulmonary overcirculation (both at rest and during 
exercise) but also causes a reduction in systemic perfusion, both at rest and during 
exercise. We also showed that the improvement in peak VO2 after ASD closure is a 
consequence of increased left ventricular stroke volume and cardiac output. ASD 
closure augments left ventricular filling, thereby increasing left ventricular preload, 
left ventricular end-diastolic diameter and ultimately left ventricular stroke volume. At 
the same time the right ventricle decreases in size, paradoxical septal motion 
disappears and ventricular interaction improves. Peak VO2 improvement was 
observed with both surgical and percutaneous closure series 32,44. Improvements 
were as early as 3 months post-op, particularly after percutaneous closure because 
of the reduced recovery time, but they appear to continue over time with further 
increase in exercise capacity in the mid-term 31,35. However, postoperative exercise 
capacity was reported lower than in normal subjects 131 presumably because of low 
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cardiac output during exercise due to reduced heart rate response during exercise 
132, or a low level of daily physical activity after surgical closure of ASD which is 
observed also in children with other types of congenital heart disease. Furthermore 
an inappropriate response of the pulmonary vasculature to exercise may also have 
a large influence on postoperative exercise capacity. Studies looking at 
cardiopulmonary responses to exercise in VSD patients have shown mixed results 
with some studies showing some limitation in peak VO2 related to increased right 
ventricular systolic pressure during exercise whereas other studies have shown no 
evidence of significantly reduced exercise tolerance either when considering large 
VSDs after closure or small VSDs in natural history. However, all studies were of 
small size and therefore no generalisation can be made for the overall VSD 
population. Children with Down’s syndrome and congenital heart defects have a 
higher predisposition to develop pulmonary hypertension 91 and this is due to many 
different factors that can be controlled or modified only to a minor extent 133. 
Therefore, exposure to long-standing increased left-to-right shunt flow where sheer 
stress on endothelium induces endothelial dysfunction followed by irreversible 
remodelling of pulmonary arteries, may have a worse effect in subjects with Down 
syndrome compared to non-syndromic children 134. These children and young adults 
are therefore more likely to have their exercise capacity affected by changes in the 
pulmonary vasculature and should receive early treatment 53.  
4.2 EXERCISE TRAINING IN SYSTEMIC RIGHT VENTRICLE  
This follow-up analysis of our randomized controlled trial on the effect of exercise 
training in adult patientswith a systemic right ventricle, demonstrates that the 
beneficial effects found after a 10-week exercise program do not persist over time. 
peak VO2, NT-proBNP levels, and quality of life remained stable in both patientswho 
had participated in exercise training, as well as in those who had not. On the other 
hand, patients who were already involved in sports at baseline, regardless of their 
study group, had an increase in exercise capacity, a decrease in NT-proBNP, and, 
more importantly, better event-free survival, as compared to those with a more 
sedentary lifestyle. 
Current guidelines appreciate the fact that physicians have been over-conservative 
in their advice on sports participation, despite the growing evidence that regular 
exercise has a positive impact on a patient's current status, as well as on the risk of 
future acquired heart disease 135. Indeed, a recent systematic review by Duppen et 
al. stressed the improved fitness in a large number of children and young adults with 
congenial heart disease who participated in an exercise training program. Moreover, 
in all reviewed articles the training programs had been performed without incidents 
136. More specifically, two other recent studies demonstrated safety and efficacy of 
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exercise in adult congenital heart disease patients. Westhoff-Bleck et al. found an 
improvement in exercise capacity and NYHA classification in patients with a 
systemic right ventricle after a 24-week training program. They found no change in 
right ventricular function, which could be due to small patient numbers, and short 
follow-up 137. In 146 patients with congenital heart disease, Tikkanen et al., found 
improved Peak VO2 in patients involved in regular exercise, as compared to those 
with a more sedentary lifestyle 138. Unfortunately, long-term effects of exercise could 
not be derived from these studies. 
Our finding that beneficial effects of exercise training are short-lived in adult patients 
with congenital heart disease is in line with previous results published on the long-
term effect of rehabilitation programs in adult patients with acquired heart disease. 
In patients after myocardial infarction who participated in an eight-week training 
program, Dorn et al. reported a diminishing effect on cardiovascular mortality as 
time since participation increased 59. Willich et al. published his findings in 2441 
patients who were enrolled in a rehabilitation program after myocardial infarction, 
coronary artery bypass grafting, or percutaneous intervention. After an initial 
improvement in cardiovascular risk factorsduring the rehabilitation program, risk 
factors deteriorated in the following 12 months 139. In contrast, in patients with 
congestive heart failure, a five-year follow-up study showed less deterioration in 
walking distance in those patients who had participated in a 24 week rehabilitation 
program, compared to controls. It has to be noted, however, that the intervention 
group remained more physically active during follow-up. This could indicate that 
favorable outcome in the intervention group is not a primary result from the 
rehabilitation program per se, but a secondary result, as patients involved in such 
programs seem inclined to increase their participation in habitual exercise 60. These 
findings were confirmed by Mueller et al., who also found superior engagement in 
physical activity in patients with congestive heart failure who had participated in 
cardiac rehabilitation, compared to controls, after a six-year follow-up period 140. As 
short-term exercise programs are no guaranty for long-term benefit, the question 
remains if long-term intervention is the answer for long-term improvement. Recently, 
Belardinelli et al., indeed found decreased deterioration of peak VO2, and NT-
proBNP levels in patients with chronic heart failure after a 10-year exercise-training 
program. 
More importantly, although the studywas not powered for the purpose, patients who 
were involved in the training program had lower rates of hospital readmission, and 
cardiac mortality 141. Whether such longterm sports participation would be 
associated with improvement of peak VO2, and NT-proBNP, and better event-free 
survival in our patients remains unclear. Although follow-up is relatively long, power 
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is insufficient to draw definite conclusions. Hence, it seems highly likely that physical 
exercise in itself, more than the actual intervention, results in improvement in peak 
VO2, and decreased hospitality and mortality in patients with heart disease, 
independent of the etiology. The European Society of Cardiology (ESC) guidelines 
on the prevention of cardiovascular disease recommend physical exercise as 
primary and secondary prevention, as it lowers the risk of hypertension and diabetes 
mellitus type II, and increases HDL cholesterol. ESC guidelines state that exercise 
decreases cardiovascular mortality in both patientswith cardiovascular disease, 
aswell as in healthy individuals 142. Unfortunately, less than 50% of Europeans are 
involved in regular exercise, which is less than in our study population (61%) 143. 
Guidelines on exercise and sports in adult patientswith congenital heart disease are 
less straightforward. As the patient group is very heterogeneous, recommendations 
should be based on the patient's ability, hemodynamic status, and the risk of 
decompensation and arrhythmias 135. In our patients, the exercise-training program 
was executed without significant incidents. Moreover, there seems to exist a 
beneficial effect of habitual sports participation. Therefore, keeping patient's ability 
inmind, our reticence to advice in favor of sports participation might be 
counterproductive. 
As with many studies on adult patients with congenital heart disease, our study 
population was relatively small. This makes the generalizability of our results limited. 
However, large-scale studies do not seem feasible in this patient group. In addition, 
only 40 out of the original 54 patients (74%) consented to participate in the current 
study, as 14 patients could not participate for a variety of reasons. Consequently, 
there is a possibility of a type 2 error. However, clinical events could be evaluated in 
50 patients. Moreover, there were no differences in baseline parameters or event 
rate compared to the participating patients. The current study was not powered to 
evaluate the effect of habitual sports participation on exercise capacity, 
neurohormone levels, or event free survival. 
This follow-up analysis on long-term effect of a 10-week exercise training 
intervention in adult patients with a systemic right ventricle, demonstrates that short-
term beneficial effects of exercise training do not persist over a three-year follow-up 
period. On the other hand, regular sports participation at baseline was associated 
with better exercise capacity, lower neurohormone levels, and increased event-free 
survival. 
4.3 EXERCISE CAPACITY IN CYANOTIC CONGENITAL HEART DISEASE 
Our study confirms the predictive value of peak VO2 in cyanotic patients with CHD 
and suggest that CPET can be used for risk stratification independently of cyanosis 
as previously reported in smaller cohorts 146-147. 
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4.4 EXERCISE CAPACITY IN UNIVENTRICULAR PHYSIOLOGY 
The prognostic value of exercise test has been inconsistent in Fontan patients with 
recently published large cohorts. Diller at al. demonstrated that exercise intolerance 
is prevalent amongst patients with a Fontan palliation and relates to increased short-
term morbidity but not increased mortality or need for cardiac transplantation in their 
cohort. Non-TCPC type of Fontan palliation, a history of clinically relevant 
arrhythmia, and signs and symptoms of heart failure were identified as strong 
prognosticators of morbidity and mortality. A combination of these factors was 
strongly related to risk of death or transplantation and was far superior to any 
measure of CPET. On the contrary Ohuchi and colleagues found peak VO2, Heart 
rate response and peak VE/VCO2 were good predictors of mortality in their cohort 
and concluded general skeletal muscle weakness, endothelial dysfunction, and 
glucose intolerance play a role in morbidity and mortality and can be improved 
through lifestyle modification. They suggest resistance exercise training may benefit 
Fontan patients with the focus of maintaining levels of peak VO2 during follow up in 
view of the rapid decline observed during adolescence 69.Our study clearly showed 
that peak VO2, either considering absolute or percent of predicted values, declines 
with age. This is consistent with what Anderson et al. 109 and Fernandes et al. 110 
previously reported in smaller cohorts. In the vast population considered this trend is 
well-rendered despite surgical tecniques improvements over the last three decades. 
4.5 EXERCISE CAPACITY IN PAEDIATRIC DILATED CARDIOMYOPATHY 
Exercise capacity measured as peak VO2 on cardiopulmonary exercise test and 
serum biomarkers levels correlate with the severity of the disease in paediatric DCM 
and showed good predictive value in terms of disease progression on the composite 
endpoint death and heart transplantation. Exercise testing, echocardiography and 
serum biomarkers are easy and widely available tests that prove valuable and 
dependable also in the follow up of children with DCM as already shown in the adult 
population. In our study biomarkers proved excellent correlation to outcome and 
when considered together peak V02 and abnormal biomarkers recognised all 
patients with good outcome (low biomarkers and high peak V02) and adverse 
outcome (high biomarkers and low peak V02). 
5. CONCLUSIONS 
Most patients born with congenital heart disease are expected to reach adulthood in 
the current era 148. Owing to the frequent late complications, however, many of them 
require and will benefit from life-long cardiac follow-up 135. Among the different 
screening tools employed during such periodic follow-up, cardiopulmonary exercise 
testing (CPET) has emerged as one of the most valuable. It is non-invasive, enables 
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risk stratification with regard to morbidity and mortality, and helps deciding on the 
need and timing of therapeutic interventions. The interpretation of CPET results in 
patients with congenital heart disease remains challenging, however. It is well 
known that exercise capacity is reduced in these patients. Relating exercise 
capacity to normal values obtained in healthy volunteers may, however, not tell the 
whole story in CHD patients. It is obvious that one cannot expect an Eisenmenger 
patient to achieve a similar peak oxygen uptake (peak VO2) as a patient with a 
simple cardiac lesion. As some level of impairment in peak VO2 is to be expected it 
may be more helpful to interpret the achieved level of exercise capacity in 
comparison with what would be usual/expected given the patient's age, gender, and 
underlying diagnosis. Comparing an individual patient to his/her peer patients may 
inform clinicians if this represents a ‘good’ or ‘bad’ exercise capacity for a given 
patient group. 
Exercise capacity has been assessed in many studies both in adult and paediatric 
patients with congenital heart disease. Protocols differ between centres and, thus, 
the results cannot be generalized to all patients with this disease. Ideally, every 
centre should develop its own database and reference values. Given the wide 
anatomic spectrum of CHD patients and the variable patient volume attached to 
different centres, this may not be practicable for most centres. In recent years many 
reviews of literature and large cohorts have been reported and offer an extremely 
helpful frame within which the clinician can interpret the exercise capacity of single 
patients given the specific anatomy, gender and kind of repair 149. 
Across the whole spectrum of CHD varying degrees of exercise limitation is 
observed even in the most simple lesions (i.e. left to right shunts due to atrial septal 
defect). Many patients with CHD have unnecessary restrictions placed upon them 
regarding physical activity and sport participation by well-meaning parents and 
physicians. As a result, many children with CHD lead sedentary lifestyles that 
persist into adulthood and present with lower levels of physical activity than optimum 
for general cardiovascular fitness. These sedentary lifestyles increase their risk for 
secondary mordidities such as hypertension, obesity, diabetes and acquired heart 
disease. The American Heart Association recently published a statement on the 
promotion of physical activity to individuals with CHD following the publication of a 
substantive body of literature regarding safety and beneficial impact on overall 
health and quality of life 151. Current guidelines appreciate the fact that physicians 
have been over-conservative in their advice on sports participation, despite the 
growing evidence that regular exercise has a positive impact on a patient's current 
status, as well as on the risk of future acquired heart disease 135. Indeed, a recent 
systematic review by Duppen et al. stressed the improved fitness in a large number 
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of children and young adults with congenial heart disease who participated in an 
exercise training program. Moreover, in all reviewed articles the training programs 
had been performed without incidents 136. 
The series we presented confirm exercise capacity is impaired, albeit at different 
levels, in every group assessed, important prognostic information can be assessed 
through exercise testing in all the diseases considered. Furthermore the benefits of 
exercise training, namely in systemic right ventricle, were evident soon after the 
exercise programme was completed but did not last in the long term as previously 
observed in long term outcomes of rehabilitation programs after myocardial 
infarction and heart failure 139,140, data on long term outcome in CHD are lacking at 
present. 
 
Looking at future perspectives the population of adults with CHD continues to grow 
in size but also evolves in anatomic and complexity case composition. Most patients 
with significant CHD are nowadays diagnosed prenatally, which often enables safe 
delivery and even occasionally intrautero therapy. There has been ongoing 
innovation and improvement of surgical and percutaneous interventions matched 
with better long-term follow-up and, with it, better understanding and treatment of 
late sequelae. The resulting survival benefit is most striking in patients with complex 
lesions, such as those born with a ‘single ventricle’. 
Survival prospects in patients with single ventricle have changed dramatically over 
the last four decades due to the advent of better and earlier diagnosis and advances 
in cardiac surgery. Clinical research, aided by advanced haemodynamic computer 
simulations, enabled optimisation of this surgical approach. The modern version of 
the ‘Fontan circulation’ (total cavopulmonary connection, TCPC) is established by 
routing the inferior vena cava flow to the pulmonary artery with a rigid conduit, 
whereas the superior vena cava is anastomosed to the right pulmonary artery using 
a Glenn shunt. 
Despite the success of this radical concept of the Fontan circulation, surgery for 
single-ventricle physiology remains palliative and not reparative, and it is inevitably 
associated with increasing long-term morbidity and mortality. Complications and late 
sequelae include progressive ventricular dysfunction, arrhythmia, thromboembolism, 
protein loosing enteropathy, liver cirrhosis, renal dysfunction and bleeding requiring 
frequent hospitalisations and interventions. Exercise performance and quality of life 
are significantly reduced in many 65,149. 
While TCPC conversion might be considered in selected cases of older generation 
of Fontan circulation most of these patients are better managed with medical 
therapy, education on risk factors and physical conditioning. Transplantation 
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remains the only definitive solution when comorbidities do not pose absolute 
contraindications. From recent estimates in the UK, it appears that the overall adult 
population with single ventricle will increase within 2023 by almost 60%, and over 
45% of these patients will be above 30 years of age, adding to the complexity of 
care 150. This underline how important it is to have structured follow up pathways 
that include functional assessment and physical conditioning or rehabilitation were 
appropriate in this cohort as well as in the general population to improve their 
prognosis.  
Exercise testing and training are becoming more and more relevant in this scenario 
to guide therapy and management but also to assess the ability in daily activities 
that play an important role in many aspects of life that have not been addressed 
specifically until now. The increasing data available enable physicians to give 
adequate advice and counseling regarding vocational or professional choices, 
suitable leisure activities and family planning according to the levels of activity 
considered safe and sustainable in the specific physiology. Further studies 
regarding exercise training and peculiar physiological changes in the univentricular 
circulation, also through modeling, will warrant further understanding and knowledge 
of issues that are specific to these patients and will help us to target interventions 
can help in improving quantity and quality of life. 
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